PDCD1 and neoplasm: Methods for enrichment of tumour-reactive TILs evolved from culture of T cells in the presence of cancer cells through selection of activated or PD-1-expressing T cells to isolation of T cells specific for the defined antigen (with a recent focus on neoantigens).